VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH AL 2020 | How age as a prognostic factor affects treatment options for ALL

Age is a prevalent prognostic factor to take into consideration when choosing acute lymphoblastic leukemia (ALL) treatment. Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, highlights the different treatment options available such as kinase inhibitors, chemotherapy, transplant and immunotherapeutic agents. He further talks about the difficulties of maintaining remission and how to overcome these issues. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter